Corvus Pharmaceuticals (CRVS) Equity Average: 2022-2025
Historic Equity Average for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $76.0 million.
- Corvus Pharmaceuticals' Equity Average rose 138.86% to $76.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.0 million, marking a year-over-year increase of 138.86%. This contributed to the annual value of $35.6 million for FY2024, which is 24.84% down from last year.
- Corvus Pharmaceuticals' Equity Average amounted to $76.0 million in Q3 2025, which was up 17.32% from $64.8 million recorded in Q2 2025.
- Over the past 5 years, Corvus Pharmaceuticals' Equity Average peaked at $85.1 million during Q2 2022, and registered a low of $22.5 million during Q4 2024.
- Moreover, its 3-year median value for Equity Average was $42.3 million (2024), whereas its average is $45.9 million.
- As far as peak fluctuations go, Corvus Pharmaceuticals' Equity Average crashed by 45.79% in 2024, and later skyrocketed by 138.86% in 2025.
- Corvus Pharmaceuticals' Equity Average (Quarterly) stood at $60.4 million in 2022, then crashed by 31.31% to $41.5 million in 2023, then slumped by 45.79% to $22.5 million in 2024, then surged by 138.86% to $76.0 million in 2025.
- Its Equity Average stands at $76.0 million for Q3 2025, versus $64.8 million for Q2 2025 and $40.9 million for Q1 2025.